FAP Isolation Using Anti-CD73 Agent Selection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for efficient and robust methods to isolate and identify fibroadipogenic progenitors (FAPs) in human skeletal muscle, as current methods are inadequate for producing high-quality preparations of FAPs for research and clinical use.

Innovation Solution

A method involving contacting a cell mixture comprising FAPs with an anti-CD73 agent, followed by separation to produce a preparation of FAPs. This method allows for the isolation and purification of FAPs using CD73 as a selection marker, enabling their differentiation into adipocytes or fibroblasts under specific conditions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If current isolation methods are used for FAPs, then the process is simple, but the purity and quality of FAP preparation is insufficient

Engineering Contradiction:

Improvepurity of FAP preparationVSAvoidcomplexity of isolation method

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent introduces CD73 as an intermediary marker to facilitate the isolation of FAPs. By using anti-CD73 agents (antibodies or aptamers) as mediators that specifically bind to CD73 expressed on FAP surfaces, the method enables selective enrichment of FAPs from mixed cell populations through flow cytometry or magnetic-activated cell sorting, thereby achieving high purity without overly complex procedures

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the selection parameter from traditional markers (PDGFRα, CD34, Sca1) to CD73, which provides superior specificity for human FAPs. This parameter change enables more effective separation and purification of FAPs while maintaining procedural simplicity through standard cell sorting techniques

Inventive Principle:

Principle #35Parameter changes

2Productivity

If traditional markers (PDGFRα, CD34, Sca1) are used, then the method is established, but the isolation efficiency and quality are inadequate

Engineering Contradiction:

Improveisolation efficiency of FAPsVSAvoidquality of FAP preparation

Core Design Contradiction:

ProductivityVSManufacturing precision

Solution Approach 1:

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces mechanical or manual isolation approaches with immunological recognition systems (anti-CD73 antibodies/aptamers) combined with automated cell sorting technologies (flow cytometry, MACS), thereby significantly improving both isolation efficiency and preparation quality

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method effectively isolates FAPs with high purity, allowing for their differentiation into adipocytes or fibroblasts, which can be used for therapeutic applications in muscle disorders.

Implementation Method 1

contacting a cell mixture comprising FAPs with an anti-CD73 agent having affinity for CD73

Methodology Applied

Scientific EffectAffinity binding: Adsorption

Data Source

PatentUS12221629B2Methods for producing fibroadipogenic progenitor cells

Publication Date: 2025.02.11 REGENTS OF THE UNIVERSITY OF MINNESOTA

AI summary

The present disclosure provides methods of producing a preparation of fibroadipogenic progenitors (FAPs) from a cell mixture. In certain embodiments, the present disclosure provides a method of producing a preparation of human FAPs from a skeletal muscle biopsy sample for later use.